Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Fuhong Hanlin (02696), which increased by 8.05% to HKD 69.80, with a trading volume of HKD 22.8793 million [2][5] - On January 9, Fuhong Hanlin presented its Phase II proof-of-concept data for PD-L1 ADC HLX43 targeting recurrent/metastatic esophageal squamous cell carcinoma (ESCC) at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) [5] - The data released indicates promising efficacy and good safety profile of HLX43 in previously treated advanced ESCC patients, demonstrating its potential as a treatment option [5] Group 2 - HLX43 has shown consistent efficacy and safety trends across multiple solid tumor indications, including non-small cell lung cancer, cervical cancer, esophageal squamous cell carcinoma, and thymic cancer [5] - The broad anti-tumor potential of HLX43 is gradually being validated through clinical practice, laying a crucial foundation for the expansion into more indications [5]

消息面上，1月9日，复宏汉霖在2026年美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO GI）上，首度公布 了其PD-L1 ADC HLX43治疗复发/转移性食管鳞癌（ESCC）的II期概念验证（POC）数据，本次发布的 数据初步验证了HLX43在经治的晚期ESCC患者中的治疗潜力，展现出令人鼓舞的疗效及良好的安全 性。HLX43已在非小细胞肺癌、宫颈癌、食管鳞癌及胸腺癌等多项实体瘤适应症中观察到持续且一致 的疗效和安全性趋势，其广谱抗肿瘤潜力正通过临床实践逐步得到验证，为后续拓展更多适应症奠定重 要基础。 智通财经APP获悉，复宏汉霖(02696)再涨超8%，截至发稿，涨8.05%，报69.8港元，成交额1864.08万港 元。 值得注意的是，第44届摩根大通医疗健康年会(JPM 2026)将于1月12–15日在美国旧金山举行。作为全球 医疗健康领域最具影响力的年度盛会之一，JPM大会被视为全球资本市场观察医药创新与产业趋势的重 要窗口。复宏汉霖执行董事兼首席执行官朱俊博士将于当地时间1月15日在大会上发表主题演讲，围绕 公司全球化2.0阶段的发展路径、创新管线布局及中长期战略规划，向国际投资人与产业界系统分享 ...

Group 1 - The core viewpoint of the articles highlights the positive market response to Fuhong Hanlin's (复宏汉霖) announcement of promising Phase II proof-of-concept data for its PD-L1 ADC HLX43 in treating recurrent/metastatic esophageal squamous cell carcinoma (ESCC), leading to an 8.05% increase in stock price [1] - The data presented at the ASCO GI conference indicates that HLX43 shows encouraging efficacy and good safety in advanced ESCC patients, supporting its broad anti-tumor potential across various solid tumor indications [1] - Fuhong Hanlin's CEO, Dr. Zhu Jun, is scheduled to deliver a keynote speech at the upcoming JPM 2026 conference, discussing the company's globalization strategy, innovation pipeline, and long-term planning, which will provide insights to international investors and industry stakeholders [2] Group 2 - The stock price of Fuhong Hanlin reached 69.8 HKD with a trading volume of 18.64 million HKD following the announcement of the clinical data [1] - The ASCO GI conference is a significant event for the medical and health sector, serving as a key platform for observing pharmaceutical innovation and industry trends [2] - The upcoming JPM conference is recognized as one of the most influential annual events in the global healthcare sector, attracting attention from capital markets [2]